CARDIAC IMPLANTS MARKET ANALYSIS

Cardiac Implants Market, by Device (Pacemaker Devices, Cardiac Resynchronization Therapy Devices, Implantable Hemodynamic Monitoring Devices, Implanted Heart Rhythm Monitors, Coronary Stents, Implantable Cardioverter Defibrillator, Heart Valve, and Others), by Application (Arrhythmias, Myocardial Ischemia, Acute Myocardial Infraction, Congestive Heart Failure, and Others), by End User (Hospitals, Emergency Medical Centers, Ambulatory Surgical Center, Home Care Settings, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Trends, and Forecast 2018 - 2027

Published In : Jun 2022
Code : CMI1176
Pages :355
Formats :
Excel and PDF
Industry : Medical Devices

Cardiac Implants MarketSize and Trends

Global cardiac implants market is estimated to be valued at US$ 35,795.6 million in 2022 and is expected to exhibit a CAGR of 8.1% during the forecast period (2022-2030).

Figure 1. Global Cardiac Implants Market in Terms of Value (US$ million), By Region, 2022

Increasing risk of cardiovascular disease due to change in lifestyle and dietary habits is expected to drive the market growth over the forecast period

There has been steady rise in cardiovascular disease due to the change in dietary habits and fast lifestyle. For instance, according to the Society of Thoracic Surgeons 2021, per month, approximately 24,000 cardiac surgeries were performed in the U.S. during December 2018 to December 2019. Hence the growing burden of heart failure, arrhythmias, etc. is expected to increase number of cardiac surgeries and thereby, drive growth of the cardiac implants market.

Figure 2. Global Cardiac Implants Market Share (%), By Device Type, 2022

Technological innovations in the field of cardiac implants is expected to evidence remarkable growth over the forecast period.

The cardiac implants market is expected to witness significant growth over the forecast period, owing to increasing focus of market players on technological innovations in the field of cardiac implants. For instance, in February 2022, Abbott, a U.S.-based medical device company, announced the initiation of its clinical trial study for evaluating the clinical effectiveness and safety of its Aveir DR Leadless Pacemaker System indicated for cardiovascular conditions such as cardiac rhythm disorder and bradycardia. This study is expected to be completed by November 2025. Aveir DR Leadless Pacemaker System is designed to provide synchronous, beat-by-beat pacing of the right atrium and right ventricle of the heart. This pacemaker is equipped with proprietary implant-to-implant (i2i) device technology, which is used for communication between two implanted leadless pacemakers, in order to regulate the heart rate.